PT  - JOURNAL ARTICLE
AU  - Wang, Yuxuan
AU  - Selvaraj, Margaret Sunitha
AU  - Li, Xihao
AU  - Li, Zilin
AU  - Holdcraft, Jacob A.
AU  - Arnett, Donna K.
AU  - Bis, Joshua C.
AU  - Blangero, John
AU  - Boerwinkle, Eric
AU  - Bowden, Donald W.
AU  - Cade, Brian E.
AU  - Carlson, Jenna C.
AU  - Carson, April P.
AU  - Chen, Yii-Der Ida
AU  - Curran, Joanne E.
AU  - de Vries, Paul S.
AU  - Dutcher, Susan K.
AU  - Ellinor, Patrick T.
AU  - Floyd, James S.
AU  - Fornage, Myriam
AU  - Freedman, Barry I.
AU  - Gabriel, Stacey
AU  - Germer, Soren
AU  - Gibbs, Richard A.
AU  - Guo, Xiuqing
AU  - He, Jiang
AU  - Heard-Costa, Nancy
AU  - Hildalgo, Bertha
AU  - Hou, Lifang
AU  - Irvin, Marguerite R.
AU  - Joehanes, Roby
AU  - Kaplan, Robert C.
AU  - Kardia, Sharon LR.
AU  - Kelly, Tanika N.
AU  - Kim, Ryan
AU  - Kooperberg, Charles
AU  - Kral, Brian G.
AU  - Levy, Daniel
AU  - Li, Changwei
AU  - Liu, Chunyu
AU  - Lloyd-Jone, Don
AU  - Loos, Ruth JF.
AU  - Mahaney, Michael C.
AU  - Martin, Lisa W.
AU  - Mathias, Rasika A.
AU  - Minster, Ryan L.
AU  - Mitchell, Braxton D.
AU  - Montasser, May E.
AU  - Morrison, Alanna C.
AU  - Murabito, Joanne M.
AU  - Naseri, Take
AU  - O’Connell, Jeffrey R.
AU  - Palmer, Nicholette D.
AU  - Preuss, Michael H.
AU  - Psaty, Bruce M.
AU  - Raffield, Laura M.
AU  - Rao, Dabeeru C.
AU  - Redline, Susan
AU  - Reiner, Alexander P.
AU  - Rich, Stephen S.
AU  - Ruepena, Muagututi’a Sefuiva
AU  - Sheu, Wayne H-H.
AU  - Smith, Jennifer A.
AU  - Smith, Albert
AU  - Tiwari, Hemant K.
AU  - Tsai, Michael Y.
AU  - Viaud-Martinez, Karine A.
AU  - Wang, Zhe
AU  - Yanek, Lisa R.
AU  - Zhao, Wei
AU  - ,
AU  - Rotter, Jerome I.
AU  - Lin, Xihong
AU  - Natarajan, Pradeep
AU  - Peloso, Gina M.
TI  - Rare variants in long non-coding RNAs are associated with blood lipid levels in the TOPMed Whole Genome Sequencing Study
AID  - 10.1101/2023.06.28.23291966
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.28.23291966
4099  - http://medrxiv.org/content/early/2023/06/29/2023.06.28.23291966.short
4100  - http://medrxiv.org/content/early/2023/06/29/2023.06.28.23291966.full
AB  - Long non-coding RNAs (lncRNAs) are known to perform important regulatory functions. Large-scale whole genome sequencing (WGS) studies and new statistical methods for variant set tests now provide an opportunity to assess the associations between rare variants in lncRNA genes and complex traits across the genome. In this study, we used high-coverage WGS from 66,329 participants of diverse ancestries with blood lipid levels (LDL-C, HDL-C, TC, and TG) in the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) program to investigate the role of lncRNAs in lipid variability. We aggregated rare variants for 165,375 lncRNA genes based on their genomic locations and conducted rare variant aggregate association tests using the STAAR (variant-Set Test for Association using Annotation infoRmation) framework. We performed STAAR conditional analysis adjusting for common variants in known lipid GWAS loci and rare coding variants in nearby protein coding genes. Our analyses revealed 83 rare lncRNA variant sets significantly associated with blood lipid levels, all of which were located in known lipid GWAS loci (in a ±500 kb window of a Global Lipids Genetics Consortium index variant). Notably, 61 out of 83 signals (73%) were conditionally independent of common regulatory variations and rare protein coding variations at the same loci. We replicated 34 out of 61 (56%) conditionally independent associations using the independent UK Biobank WGS data. Our results expand the genetic architecture of blood lipids to rare variants in lncRNA, implicating new therapeutic opportunities.Competing Interest StatementP.N. reports investigator-initiated grant support from Amgen, Apple, AstraZeneca, and Boston Scientific, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Genentech, TenSixteen Bio, and Novartis, scientific advisory board membership of geneXwell and TenSixteen Bio, and spousal employment at Vertex, all unrelated to the present work. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. L.M.R is a consultant for the TOPMed Administrative Coordinating Center (through Westat). M.E.M. receives funding from Regeneron Pharmaceutical Inc. unrelated to this work. X. Lin is a consultant of AbbVie Pharmaceuticals and Verily Life Sciences. The remaining authors declare no competing interests.Funding StatementWhole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). G.M.P. is supported by NIH grants R01HL142711 and R01HL127564. P.N. is supported by grants from the National Heart, Lung, and Blood Institute (R01HL142711, R01HL148050, R01HL151283, R01HL148565, R01HL135242, R01HL151152), Fondation Leducq (TNE-18CVD04), and Massachusetts General Hospital (Paul and Phyllis Fireman Endowed Chair in Vascular Medicine). X.Lin is supported by grants R35-CA197449, U19-CA203654, R01-HL113338, and U01-HG009088. We like to acknowledge all the grants that supported this study, R01 HL121007, U01 HL072515, R01 AG18728, X01HL134588, HL 046389, HL113338, and 1R35HL135818, K01 HL135405, R03 HL154284, U01HL072507, R01HL087263, R01HL090682, P01HL045522, R01MH078143, R01MH078111, R01MH083824, U01DK085524, R01HL113323, R01HL093093, R01HL140570, R01HL142711, R01HL127564, R01HL148050, R01HL148565, HL105756, and Leducq TNE-18CVD04. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed and UK Biobank. The full study specific acknowledgements and NHLBI TOPMed Fellowship acknowledgement are detailed in Supplementary Text.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Boston University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual whole-genome sequence data for TOPMed and harmonized lipids at individual sample level are available through restricted access via the TOPMed dbGaP Exchange area. Summary level genotype data from TOPMed are available through the BRAVO browser (https://bravo.sph.umich.edu/). The UK Biobank (UKB) whole-genome sequence data can be accessed through UKB Research Analysis Platform (RAP), through the UKB approval system (https://www.ukbiobank.ac.uk). The dbGaP accessions for TOPMed cohorts are as follows: Old Order Amish (Amish) phs000956 and phs00039;Atherosclerosis Risk in Communities study (ARIC) phs001211 and phs000280; Mt Sinai BioMe Biobank (BioMe) phs001644 and phs000925; Coronary Artery Risk Development in Young Adults (CARDIA) phs001612 and phs000285; Cleveland Family Study (CFS) phs000954 and phs000284; Cardiovascular Health Study (CHS) phs001368 and phs000287; Diabetes Heart Study (DHS) phs001412 and phs001012; Framingham Heart Study (FHS) phs000974 and phs000007; Genetic Studies of Atherosclerosis Risk (GeneSTAR) phs001218 and phs000375; Genetic Epidemiology Network of Arteriopathy (GENOA) phs001345 and phs001238; Genetic Epidemiology Network of Salt Sensitivity (GenSalt) phs001217 and phs000784; Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) phs001359 and phs000741; Hispanic Community Health Study - Study of Latinos (HCHS_SOL) phs001395 and phs000810; Hypertension Genetic Epidemiology Network and Genetic Epidemiology Network of Arteriopathy (HyperGEN) phs001293 and phs001293; Jackson Heart Study (JHS) phs000964 and phs000286; Multi-Ethnic Study of Atherosclerosis (MESA) phs001416 and phs000209; Massachusetts General Hospital Atrial Fibrillation Study (MGH_AF) phs001062 and phs001001; San Antonio Family Study (SAFS) phs001215 and phs000462; Samoan Adiposity Study (SAS) phs000972 and phs000914; Taiwan Study of Hypertension using Rare Variants (THRV) phs001387 and phs001387; Women's Health Initiative (WHI) phs001237 and phs000200.